Ajooni Biotech peers

·UnclassifiedChart ›

Companies like Ajooni Biotechlatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

AJOONI₹2.90

Ajooni Biotech Limited

· Unclassified
₹ CrorePeersTOUCHWOODRKECRAJMETBANKAAAKASHGANGAFORGEGLOBEAGROPHOSMcap ₹50 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
AJOONI
FY26
TOUCHWOOD
FY26
RKEC
FY25
RAJMET
FY26
Peer
Average
Valuation — at last close
P/E11.60×15.02×◆ 2.14×—8.58× +35%
P/B0.55×1.38×◆ 0.23×1.44×1.01× -46%
EV/EBITDA10.76×7.03×◆ 3.72×30.69×13.81× -22%
Market Cap₹50 Cr₹60.9 Cr₹42.8 Cr₹81 Cr₹61.6 Cr -19%
Growth
Revenue CAGR 3Y◆ 34.78%26.65%26.04%-36.51%5.39% +545%
Revenue CAGR 5Y◆ 29.01%——-16.03%-16.03% +281%
Net Income CAGR 3Y◆ 56.64%18.26%41.19%—29.73% +91%
Revenue YoY (latest Q)◆ 103.06%-76.56%-72.56%-29.68%-59.60% +273%
Net Income YoY (latest Q)-44.74%-70.11%-79.24%◆ 119.60%-9.92% -351%
Profitability
EBITDA Margin3.43%8.70%◆ 12.20%1.16%7.35% -53%
Net Income Margin2.37%◆ 5.41%4.75%-0.12%3.35% -29%
Return on Common Equity4.82%9.62%◆ 11.21%-0.57%6.75% -29%
Return on Capital Employed4.42%11.83%◆ 19.80%2.79%11.47% -61%
Return on Assets4.01%◆ 7.55%3.83%-0.24%3.71% +8%
Credit & Quality
Total Debt/Equity0.19×◆ 0.08×1.04×0.24×0.45× -58%
Interest Coverage5.55×◆ 14.98×2.19×0.60×5.92× -6%
Scale — latest FY
Revenue / Total Income₹182 Cr₹74.6 Cr₹422 Cr₹263 Cr₹253 Cr -28%
Net Income₹4.3 Cr₹4 Cr₹20 Cr−₹0.3 Cr₹7.9 Cr -45%
Total Assets₹120 Cr₹57.4 Cr₹581 Cr₹119 Cr₹252 Cr -52%
EPS₹0.25₹3.66₹8.35₹0₹4 -94%
Book Value per Share₹5.29₹39.81₹78.65₹2.04₹40.17 -87%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.